BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tipelukast readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tipelukast\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05464784-8091@assetmemo.bio
DTSTAMP:20261121T004544Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tipelukast: Phase 2 readout est. (NCT05464784)
DESCRIPTION:Tipelukast\, phase 2\, Type 2 Diabetes.\nStudy: MN-001 in Non-a
 lcoholic Fatty Liver Disease\, Type 2 Diabetes Mellitus\, and Hypertriglyc
 eridemia\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tipelukast#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05464784
URL:https://assetmemo.bio/drug/tipelukast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
